.svg){kind=small}
Keith Berelowitz, Director of Operations at Richmond Pharmacology, outlines in an article for Health Investor how innovations in the design and delivery of clinical trials are generating time and cost savings for industry.
Brexit and COVID-19 have shed a light on the importance of swift and cost-effective clinical trial development within the UK. Adaptive trials are a game changing process within clinical research and use of these protocols by CROs such as Richmond Pharmacology has demonstrated considerable value for sponsors and investors. These benefits include faster trial assessment and conclusion and the efficient use of resource compared to more rigid traditional clinical trial processes. Ultimately these new processes also help to speed the path of promising new medicines to patients as well.
Despite the advancements brought to the clinical environment by adaptive trials, these processes have not become standard practice yet among all CROs. As clinical research becomes ever more important within UK’s economic, medical, and R&D environments, it is important that organisations – and their investors - re-evaluate how they plan, and commission clinical research as well as understand the benefits of using new trial designs across systems and territories.
Read the article in full, visit - www.healthinvestor.co.uk/feature/game-changer/
